ienz_a_1545226_sm2849.docx (14.47 MB)

Structure-guided design of anti-cancer ribonucleotide reductase inhibitors

Download (14.47 MB)
journal contribution
posted on 07.01.2019, 08:57 by Tessianna A. Misko, Yi-Ting Liu, Michael E. Harris, Nancy L. Oleinick, John Pink, Hsueh-Yun Lee, Chris G. Dealwis

Ribonucleotide reductase (RR) catalyses the rate-limiting step of dNTP synthesis, establishing it as an important cancer target. While RR is traditionally inhibited by nucleoside-based antimetabolites, we recently discovered a naphthyl salicyl acyl hydrazone-based inhibitor (NSAH) that binds reversibly to the catalytic site (C-site). Here we report the synthesis and in vitro evaluation of 13 distinct compounds (TP1-13) with improved binding to hRR over NSAH (TP8), with lower KD’s and more predicted residue interactions. Moreover, TP6 displayed the greatest growth inhibiting effect in the Panc1 pancreatic cancer cell line with an IC50 of 0.393 µM. This represents more than a 2-fold improvement over NSAH, making TP6 the most potent compound against pancreatic cancer emerging from the hydrazone inhibitors. NSAH was optimised by the addition of cyclic and polar groups replacing the naphthyl moiety, which occupies the phosphate-binding pocket in the C-site, establishing a new direction in inhibitor design.


This study was supported by NIH funding to P.I.: Dr. Chris G. Dealwis (R01GM100887), Case Comprehensive Cancer Centre CTSC pilot grant and Council to Advance Human Health. Drs. Lee and Dealwis were funded by the Taipei Medical School, Taiwan-CWRU grant. This research was supported in part by the Translational Research Shared resource of the Case Comprehensive Cancer Centre (P30CA043703) and Center for Scientific Review.